Zum Hauptinhalt springen
Hochschulbibliothek der Hochschule Düsseldorf

In vitro response and gene expression of human retinal Müller cells treated with different anti-VEGF drugs.

Cáceres-Del-Carpio, J ; Moustafa, MT ; et al.
In: Experimental eye research, Jg. 191 (2020-02-01), S. 107903
academicJournal

Titel:
In vitro response and gene expression of human retinal Müller cells treated with different anti-VEGF drugs.
Autor/in / Beteiligte Person: Cáceres-Del-Carpio, J ; Moustafa, MT ; Toledo-Corral, J ; Hamid, MA ; Atilano, SR ; Schneider, K ; Fukuhara, PS ; Costa, RD ; Norman, JL ; Malik, D ; Chwa, M ; Boyer, DS ; Limb, GA ; Kenney, MC ; Kuppermann, BD
Zeitschrift: Experimental eye research, Jg. 191 (2020-02-01), S. 107903
Veröffentlichung: London : Academic Press ; <i>Original Publication</i>: London., 2020
Medientyp: academicJournal
ISSN: 1096-0007 (electronic)
DOI: 10.1016/j.exer.2019.107903
Schlagwort:
  • Actins genetics
  • Angiogenic Proteins genetics
  • Apoptosis
  • Apoptosis Regulatory Proteins genetics
  • Bevacizumab pharmacology
  • Carrier Proteins genetics
  • Cell Line
  • Cell Survival
  • Ependymoglial Cells metabolism
  • Glial Fibrillary Acidic Protein genetics
  • Humans
  • Inflammation genetics
  • Membrane Potential, Mitochondrial physiology
  • Oxidative Stress genetics
  • Ranibizumab pharmacology
  • Reactive Oxygen Species metabolism
  • Real-Time Polymerase Chain Reaction
  • Receptors, Vascular Endothelial Growth Factor
  • Recombinant Fusion Proteins pharmacology
  • Angiogenesis Inhibitors pharmacology
  • Ependymoglial Cells drug effects
  • Gene Expression physiology
  • Vascular Endothelial Growth Factor A antagonists & inhibitors
Sonstiges:
  • Nachgewiesen in: MEDLINE
  • Sprachen: English
  • Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • Language: English
  • [Exp Eye Res] 2020 Feb; Vol. 191, pp. 107903. <i>Date of Electronic Publication: </i>2020 Jan 03.
  • MeSH Terms: Angiogenesis Inhibitors / *pharmacology ; Ependymoglial Cells / *drug effects ; Gene Expression / *physiology ; Vascular Endothelial Growth Factor A / *antagonists & inhibitors ; Actins / genetics ; Angiogenic Proteins / genetics ; Apoptosis ; Apoptosis Regulatory Proteins / genetics ; Bevacizumab / pharmacology ; Carrier Proteins / genetics ; Cell Line ; Cell Survival ; Ependymoglial Cells / metabolism ; Glial Fibrillary Acidic Protein / genetics ; Humans ; Inflammation / genetics ; Membrane Potential, Mitochondrial / physiology ; Oxidative Stress / genetics ; Ranibizumab / pharmacology ; Reactive Oxygen Species / metabolism ; Real-Time Polymerase Chain Reaction ; Receptors, Vascular Endothelial Growth Factor ; Recombinant Fusion Proteins / pharmacology
  • References: Ophthalmology. 2010 Jun;117(6):1124-1133.e1. (PMID: 20381871) ; Ophthalmic Physiol Opt. 2009 Sep;29(5):557-64. (PMID: 19689550) ; Br J Ophthalmol. 2013 Jul;97(7):917-23. (PMID: 23686000) ; Ophthalmology. 2012 Jul;119(7):1388-98. (PMID: 22555112) ; Glia. 2013 May;61(5):651-78. (PMID: 23440929) ; Br J Ophthalmol. 2014 Jun;98 Suppl 1:i11-16. (PMID: 24836865) ; J Immunol Methods. 1983 Dec 16;65(1-2):55-63. (PMID: 6606682) ; Asia Pac J Ophthalmol (Phila). 2017 Nov-Dec;6(6):561-568. (PMID: 28971631) ; Adv Exp Med Biol. 2014;801:409-15. (PMID: 24664725) ; N Engl J Med. 2006 Oct 5;355(14):1432-44. (PMID: 17021319) ; Proc Natl Acad Sci U S A. 2007 May 15;104(20):8287-92. (PMID: 17485670) ; BMJ. 2010 Jun 09;340:c2459. (PMID: 20538634) ; Retina. 2019 Apr;39(4):648-655. (PMID: 29232334) ; Br J Ophthalmol. 2015 Aug;99(8):1055-9. (PMID: 25677668) ; Br J Ophthalmol. 2005 Nov;89(11):1510-7. (PMID: 16234463) ; Ophthalmic Surg Lasers Imaging Retina. 2015 Jan;46(1):91-4. (PMID: 25559518) ; N Engl J Med. 2006 Oct 5;355(14):1419-31. (PMID: 17021318) ; Retina. 2017 Oct;37(10):1859-1865. (PMID: 28060148) ; J Gerontol A Biol Sci Med Sci. 2014 Jun;69 Suppl 1:S4-9. (PMID: 24833586) ; JAMA Ophthalmol. 2013 Feb;131(2):139-45. (PMID: 23544200) ; Br J Ophthalmol. 2012 Feb;96(2):179-84. (PMID: 22250209) ; Cell Prolif. 2005 Oct;38(5):301-11. (PMID: 16202038) ; Ophthalmology. 2012 Aug;119(8):1658-65. (PMID: 22537617) ; Invest Ophthalmol Vis Sci. 2015 May;56(5):3279-86. (PMID: 26024110) ; Mol Vis. 2011;17:2738-50. (PMID: 22065927) ; Front Cell Neurosci. 2019 Aug 16;13:376. (PMID: 31474836) ; Eye (Lond). 2008 Apr;22(4):551-5. (PMID: 17464309) ; Histol Histopathol. 2003 Oct;18(4):1205-18. (PMID: 12973689) ; Graefes Arch Clin Exp Ophthalmol. 2010 Jun;248(6):819-24. (PMID: 20169356) ; J Immunol Methods. 1995 Sep 25;185(2):249-58. (PMID: 7561136) ; Indian J Ophthalmol. 2015 May;63(5):469-70. (PMID: 26139820) ; Exp Eye Res. 1996 Feb;62(2):155-69. (PMID: 8698076) ; Immunol Rev. 2015 May;265(1):63-74. (PMID: 25879284) ; Mol Vis. 2010 May 01;16:793-9. (PMID: 20454698) ; Brain Res. 2012 Oct 10;1478:55-63. (PMID: 23046588) ; Am J Ophthalmol. 2013 Mar;155(3):429-437.e7. (PMID: 23218699) ; Exp Eye Res. 2017 Jul;160:1-10. (PMID: 28419863) ; J Ocul Pharmacol Ther. 2016 Mar;32(2):102-8. (PMID: 26624556) ; Invest Ophthalmol Vis Sci. 2002 Mar;43(3):864-9. (PMID: 11867609) ; Br J Ophthalmol. 2012 Jul;96(7):1023-8. (PMID: 22539748) ; Mol Neurobiol. 2019 Dec;56(12):8124-8135. (PMID: 31190144) ; Br J Ophthalmol. 2017 Feb;101(2):166-169. (PMID: 27190127) ; Ophthalmology. 2014 Jan;121(1):150-161. (PMID: 24084496) ; Retina. 2006 May-Jun;26(5):512-8. (PMID: 16770256) ; Ophthalmology. 2010 Jun;117(6):1102-1112.e1. (PMID: 20398941) ; PLoS One. 2018 Nov 26;13(11):e0207913. (PMID: 30475883) ; Br J Ophthalmol. 2017 Oct;101(10):1374-1376. (PMID: 28270485) ; BMC Res Notes. 2014 Sep 08;7:617. (PMID: 25201034) ; Int J Retina Vitreous. 2016 Feb 1;2:3. (PMID: 27847621) ; Adv Exp Med Biol. 2016;854:31-7. (PMID: 26427390) ; Graefes Arch Clin Exp Ophthalmol. 2007 Dec;245(12):1837-42. (PMID: 17347807) ; Prog Retin Eye Res. 2008 Nov;27(6):579-95. (PMID: 18775790) ; N Engl J Med. 2015 Mar 26;372(13):1193-203. (PMID: 25692915) ; J Cell Biol. 1978 Sep;78(3):675-84. (PMID: 29902)
  • Grant Information: MR/P01660X/1 United Kingdom MRC_ Medical Research Council; R01 EY027363 United States EY NEI NIH HHS
  • Substance Nomenclature: 0 (11-cis-retinal-binding protein) ; 0 (ACTA2 protein, human) ; 0 (Actins) ; 0 (Angiogenesis Inhibitors) ; 0 (Angiogenic Proteins) ; 0 (Apoptosis Regulatory Proteins) ; 0 (Carrier Proteins) ; 0 (GFAP protein, human) ; 0 (Glial Fibrillary Acidic Protein) ; 0 (Reactive Oxygen Species) ; 0 (Recombinant Fusion Proteins) ; 0 (VEGFA protein, human) ; 0 (Vascular Endothelial Growth Factor A) ; 15C2VL427D (aflibercept) ; 2S9ZZM9Q9V (Bevacizumab) ; EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor) ; ZL1R02VT79 (Ranibizumab)
  • Entry Date(s): Date Created: 20200107 Date Completed: 20200724 Latest Revision: 20240313
  • Update Code: 20240313
  • PubMed Central ID: PMC7058176

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

oder
oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

oder
oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

xs 0 - 576
sm 576 - 768
md 768 - 992
lg 992 - 1200
xl 1200 - 1366
xxl 1366 -